Nour K Majbour

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6005953/publications.pdf

Version: 2024-02-01

34 papers	1,943 citations	331259 21 h-index	377514 34 g-index
35 all docs	35 docs citations	35 times ranked	2475 citing authors

#	Article	IF	Citations
1	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinsonâ€™s disease. Molecular Neurodegeneration, 2016, 11, 7.	4.4	198
2	Levels of cerebrospinal fluid Î±-synuclein oligomers are increased in Parkinsonâ€™s disease with dementia and dementia with Lewy bodies compared to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 25.	3.0	169
3	Differential role of CSF alpha-synuclein species, tau, and AÃŽÂ²42 in Parkinson's Disease. Frontiers in Aging Neuroscience, 2014, 6, 53.	1.7	139
4	Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. Journal of Neuroinflammation, 2018, 15, 129.	3.1	131
5	Longitudinal changes in CSF alphaâ€synuclein species reflect Parkinson's disease progression. Movement Disorders, 2016, 31, 1535-1542.	2.2	120
6	Generation and characterization of novel conformation-specific monoclonal antibodies for Î±-synuclein pathology. Neurobiology of Disease, 2015, 79, 81-99.	2.1	116
7	Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. Scientific Reports, 2017, 7, 16533.	1.6	110
8	Parkinsonâ€™s disease biomarkers based on Î±â€synuclein. Journal of Neurochemistry, 2019, 150, 626-636.	2.1	104
9	Safety and immunogenicity of the Î±-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurology, The, 2020, 19, 591-600.	4.9	83
10	Î±â€Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. Movement Disorders, 2018, 33, 1724-1733.	2.2	79
11	Brain propagation of transduced Î±-synuclein involves non-fibrillar protein species and is enhanced in Î±-synuclein null mice. Brain, 2016, 139, 856-870.	3.7	78
12	Differential effects of immunotherapy with antibodies targeting Î±-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiology of Disease, 2017, 104, 85-96.	2.1	72
13	CSF or Serum Neurofilament Light Added to Î±â€Synuclein Panel Discriminates Parkinson's From Controls. Movement Disorders, 2020, 35, 288-295.	2.2	69
14	Î±-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2109617119.	3.3	60
15	Elevated levels of cerebrospinal fluid ÃŽÂ±-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Frontiers in Aging Neuroscience, 2014, 6, 248.	1.7	59
16	Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 40263.	1.6	51
17	Holocranohistochemistry enables the visualization of Î±-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. Journal of Neural Transmission, 2017, 124, 721-738.	1.4	42
18	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration, 2016, 11, 61.	4.4	39

#	Article	IF	Citations
19	Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders. Molecular Therapy, 2016, 24, 746-758.	3.7	38
20	CSF total and oligomeric Î±-Synuclein along with TNF-Î± as risk biomarkers for Parkinsonâ€™s disease: a study in LRRK2 mutation carriers. Translational Neurodegeneration, 2020, 9, 15.	3.6	32
21	Ser129 phosphorylation of endogenous Î±-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function. Neurobiology of Disease, 2015, 78, 100-114.	2.1	24
22	Cerebrospinal Î±â€Synuclein Oligomers Reflect Disease Motor Severity in <scp>DeNoPa</scp> Longitudinal Cohort. Movement Disorders, 2021, 36, 2048-2056.	2.2	21
23	Investigating the presence of doubly phosphorylated Î±â€synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases. Brain Pathology, 2020, 30, 831-843.	2.1	15
24	Cerebrospinal Fluid Î±-Synuclein Species in Cognitive and Movements Disorders. Brain Sciences, 2021, 11, 119.	1.1	14
25	Small molecule inhibitors of Î±-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Molecular Neurodegeneration, 2021, 16, 77.	4.4	13
26	Generation of monoclonal antibodies against phosphorylated Î±-Synuclein at serine 129: Research tools for synucleinopathies. Neuroscience Letters, 2020, 725, 134899.	1.0	12
27	Fibrillar form of Î±-synuclein-specific scFv antibody inhibits Î±-synuclein seeds induced aggregation and toxicity. Scientific Reports, 2020, 10, 8137.	1.6	9
28	Novel engineered nanobodies specific for Nâ€terminal region of alphaâ€synuclein recognize Lewyâ€body pathology and inhibit inâ€vitro seeded aggregation and toxicity. FEBS Journal, 2022, 289, 4657-4673.	2.2	9
29	Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein. Frontiers in Aging Neuroscience, 2021, 13, 638718.	1.7	8
30	Cognitive impairment in Parkinson's disease. Lancet Neurology, The, 2017, 16, 23-24.	4.9	7
31	CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinsonâ€²s Disease. International Journal of Molecular Sciences, 2020, 21, 8519.	1.8	7
32	Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?. Diagnosis, 2020, 7, 373-376.	1.2	2
33	P2â€163: Performance Evaluation of New Absorbanceâ€Based Elisas for Measuring Different Alphaâ€Synuclein (Aâ€SYN) Species in CSF and Plasma. Alzheimer's and Dementia, 2016, 12, P677.	0.4	1
34	P4â€316: Standardization of Preâ€Analytical Procedures for Collection and Storage of CSF for the Measurement of Neurogranin Trunc P75 and aâ€Synuclein. Alzheimer's and Dementia, 2016, 12, P1155.	0.4	0